NetraMark Holdings Inc Stock Price, News & Analysis

NetraMark Holdings (OTCQB: AINMF) has signed a contract with Asklepion Pharmaceuticals to deploy its NetraAI platform for analyzing results from a pivotal Phase III pediatric clinical trial. The study, CIT-003-01, evaluates the efficacy of intravenous L-citrulline in preventing acute lung injury in children undergoing cardiopulmonary bypass surgery for congenital heart defects.

NetraAI's technology will utilize explainable AI and generative modeling to optimize trial outcomes through enhanced patient stratification and identification of responder personas. The partnership aims to demonstrate L-citrulline's benefits in specific patient subgroups and inform future study designs.

NetraMark Holdings (OTCQB: AINMF), an AI company focused on clinical trials transformation, announced its CEO George Achilleos will attend Canaccord Genuity's 45th Annual Growth Conference from August 12-14, 2025, in Boston, Massachusetts.

The company's platform, NetraAI, is designed to enhance clinical development by identifying explainable patient subpopulations, uncovering drug response drivers, reducing placebo effects, and improving patient selection strategies. During the conference, the CEO will be available for one-on-one meetings with institutional investors, pharmaceutical sponsors, and strategic partners to discuss the platform's applications across therapeutic areas.

NetraMark Holdings (OTCQB: AINMF) has partnered with Pentara Corporation to launch an AI-powered site intelligence tool for enhancing clinical trial integrity. The collaboration introduces a novel system that calculates a Paradox Risk score to detect anomalous participant behavior and site-level irregularities using pre-randomization data.

The partnership combines NetraMark's AI technology with Pentara's expertise in clinical data analysis, particularly in degenerative diseases. The tool integrates information-theoretic variability, singleton occurrence frequencies, and co-association penalties to identify potential data integrity issues that could affect trial outcomes.

This strategic alliance aims to enable proactive risk mitigation, implement scalable site monitoring with real-time alerts, and enhance confidence in efficacy outcomes across heterogeneous clinical trials.

NetraMark Holdings (OTCQB: AINMF) has entered into an agreement with AlgoTherapeutix (AlgoTx) to enhance clinical trial design for ATX01, a treatment for chemotherapy-induced peripheral neuropathy (CIPN). NetraMark will deploy its NetraAI platform to analyze patient-level data from the ATX01 program.

The collaboration aims to leverage NetraAI's unique technology to identify responder personas, explore drug and placebo response variables, and develop enrichment strategies for future trials. The partnership will focus on creating customized AI models and interactive tools that enable hypothesis testing and precise characterization of patient subpopulations, with the goal of generating validated, explainable insights for regulatory submission.

NetraMark Holdings has released a groundbreaking study demonstrating that its AI platform, NetraAI, significantly outperforms ChatGPT, DeepSeek, and traditional machine learning in analyzing clinical trial data. The study tested the platforms using three complex datasets: CATIE (schizophrenia), CAN-BIND (depression), and COMPASS (pancreatic cancer). NetraAI achieved remarkable results, including accuracy rates of 85-100% across trials, while identifying clinically meaningful patient subgroups using only 2-4 variables. In contrast, ChatGPT and DeepSeek failed to generate statistically valid insights. NetraAI's success stems from its unique mathematical foundation in dynamical systems theory and evolutionary computation, making it particularly effective for clinical trial optimization and patient stratification. The platform's ability to identify specific patient subgroups and provide interpretable results could significantly reduce trial failures and improve drug development success rates.

NetraMark Holdings announced that its founder Dr. Joseph Geraci led the authorship of a significant publication in the Journal of the Society for Clinical Data Management about AI/ML integration in clinical trials. The paper, co-authored with experts from FDA, EMA, DKMA, and major pharmaceutical companies, explores seven real-world use cases for AI in clinical trials, including smart data query, patient stratification, and external control arms. The publication addresses key challenges like AI model generalizability and ethical considerations such as privacy controls. The paper aligns with NetraMark's NetraAI platform capabilities, which focuses on small dataset modeling, explainability, and patient enrichment strategies for clinical trials.

NetraMark Holdings Inc. (CSE: AIAI, OTCQB: AINMF), an AI solutions company focused on pharmaceutical clinical trial design, held its Annual General Meeting on June 9th, 2025. During the meeting, shareholders approved all proposed matters outlined in the May 5th Management Information Circular. The company announced the election of its board members, including PJ Haley, Dr. Joseph Geraci, George Achilleos, and Andrew Parks, with Parks being subsequently appointed as Chairman of the Board.

NetraMark Holdings (CSE: AIAI) (OTCQB: AINMF), an AI company specializing in clinical trials analytics, has announced a shareholder conference call scheduled for Tuesday, April 15, 2025, from 4:00-4:30pm EST. CEO George Achilleos will lead the discussion on recent developments and growth strategies.

Key highlights include a strategic partnership with Worldwide Clinical Trials, which is integrating NetraAI into various clinical trials, particularly in neuroscience and oncology. The company will discuss its regulatory alignment strategy, focusing on how its explainable AI capabilities support clinical trials and FDA submissions.

The call will also showcase NetraAI's technological differentiation, highlighting its ability to identify subpopulations in small datasets and reduce overfitting. Additionally, NetraMark has extended its agreement with 1502656 B.C for public relations services, with additional compensation of $200,000 CDN for a six-month term.

NetraMark Holdings (OTCQB: AINMF) has announced a global partnership with Worldwide Clinical Trials to enhance clinical trial design using AI technology. The collaboration integrates NetraMark's proprietary NetraAI platform into Worldwide's service offerings, initially focusing on Phase 2 neuroscience and oncology trials, with plans to expand across all therapeutic areas.

The partnership combines Worldwide's three decades of clinical execution excellence and 11 consecutive CRO Leadership Awards with NetraMark's advanced AI solution. The integration aims to optimize clinical trials by identifying hidden patient subpopulations within complex datasets, improving trial efficiency, and delivering regulatory-aligned insights.

Key benefits include accelerated development timelines, refined patient stratification, reduced placebo response variability, and enhanced trial power. The collaboration is expected to enable more informed protocol development, faster decision-making, and improved patient targeting, ultimately leading to fewer required patients per trial, reduced timelines, and lower costs for sponsors.